Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

NCT00724360 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Difficulties of recruitment

Conditions

Relapsed/Refractory Leukemia

Interventions

DRUG: Herceptin (trastuzumab)

Sponsor

Nantes University Hospital